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The authors report a case of hormonally silent duodenal somatostatinoma. The main clinical
features, the natural history and the currently available therapies of these rare neoplasms are
described on the basis of this case and of the scientific literature. Although the antiblastic
therapies are still debated, the patient showed a surprising outcome following chemotherapy.
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INTRODUCTION
Somatostatinoma is a neuroendocrine neoplasm de-
rived from the D cells of the APUD system firstly
described by Pearse 1. This tumor is rare and the duo-
denal location has been described in less than 10 cases.
Unlike pancreatic somatostatinoma, described in the
late 70’s2’3, which generally produces a clinical syn-
drome (diabetes, steatorrhea, hypochloridria, dyspep-
sia), duodenal somatostatinoma may be completely
asymptomatic.
We report a case of silent duodenal somatos-
tatinoma with hepatic metastases that has been treated
by chemotherapy obtaining a surprisingly steady
response.
CASE REPORT
The patient was a 43-year-old white woman with a
pancreatic pseudocyst previously treated with a cysto-
jejunostomy and a Y-en-Roux gastro-enterostomy
and a past history of NANB viral hepatitis. She suf-
fered from dyspepsia for about 1 year. Some months
prior to admission the patient had undergone a gas-
troduodenoscopy because of the onset ofpost-prandial
vomiting and epigastric pain radiating to the back. The
endoscopist noticed a patent gastro-enterostomy and
a marked dilatation of the duodenal bulb due to
a stenosis in the second part of the duodenum.
On admission, the physical examination was com-
pletely negative. The general condition and the nutri-
tional status were good. Routine blood analysis
showed abnormal liver function tests (elevated alkaline
phosphatase, SGPT and SGOT) and a mild anemia
(Hb 12.7 g/dl); tumor markers (CEA, CA 19-9, CA 50,
CA 125) were normal. A further endoscopy confirmed
the duodenal stenosis and a biopsy was obtained; the
histology suggested a neuroendocrine neoplasm and
immunohistochemistry was positive for somatostatin,
NSE and chromogranin. A plasma somatostatin level
obtained was 285 pg/ml (normal range 70-150 pg/ml);
urine 5-hidroxyindolacetic acid was slightly increased.
Abdominal US showed two slightly hyperechogenic
lesions (15 and 22 mm, respectively) with hypoechogenic
edges in the right hepatic lobe and a solid, hypodense
mass (3 cm in diameter) located medially and next to
the duodenum.
A CT scan (Fig. 1) revealed duodenal dilatation with
a mass protruding into the visceral lumen; hepatic
masses showed an angiomatous appearance after the
injection of contrast medium.
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Figure Abdominal CT scan showing duodenal dilatation with a mass protruding into the visceral lumen.
A selective angiography of the celiac artery and its
branches (Fig. 2) noticed a hypervascularized mass in
the second part of the duodenum, containing micro
arterovenous fistulae with stasis of the contrast medium;
one ofthe hepatic lesions in the fight lobe had a pathologic
vascular appearance but not of an angiomatous type.
At laparotomy, multiple bilateral hepatic metastases
were found. Frozen sections revealed metastases of
apudoma and definitive immunohistochemistry
(Fig. 3) confirmed the diagnosis of somatostatinoma.
The postoperative period was uneventful. Before dis-
charge, the patient underwent a 1311-MIBG scintiscan
to evaluate the usefulness of radiometabolic therapy;
the images obtained showed a dishomogeneous uptake
which contraindicated nuclide treatment.
In the following months, ambulatory chemotherapy
was given (calcium L-folinate 100 mg/m
2 and 5-FU
370 mg/m
2 i.v. for 5 days every 28 days, and e-2b-
Interferon 3,000,000 U subcutaneously on alternate
days without interruption) for 8 cycles.
The comprehensive evaluation ofthe response to the
therapy showed steady disease lasting 8 months. Infact,
a further abdominal US revealed, 9 months after sur-
gery, increased diameter of the hepatic metastases and
chemotherapy was discontinued.
The patient is alive 24 months after diagnostic
laparotomy; she is in good conditions and does not
complain of clinical symptoms of somatostatinoma
syndrome. She has undergone two further US scans
that have not shown any further growth of the hepatic
lesions. The levels of urine 5-hidroxyindolacetic acid
and plasma somatostatin were in the normal ranges.
DISCUSSION
Somatostatinoma has been more frequently observed
in the pancreas, 45% of the described cases were
located there. Duodenal location, first reported in
19794,5 is rare and accounts for 19% of the overall
literature. This neoplasm may produce a clinicalsyn-
drome including diabetes, steatorrhea, hypochlorhid-
ria and dyspepsia; cholelithiasis and anaemia have also
been described6. However, it should be mentioned that
in a recent review7 no symptoms were specific enough
to be considered as pathognomonic.
Duodenal somatostatinoma is hormonally "silent"
in most cases 8. High levels of other hormones (cal-
citonin, insulin, Pancreatic Polypeptide, VIP, ACTH,
5-HIAA) have been described in plasma or as cell
immunoreactivity. The expanding neoplasm produces
symptoms of alimentary tract obstruction (dyspepsia,
duodenal stenosis, obstructive jaundice) so it may beDUODENAL MALIGNANT SOMATOSTATINOMA 265
Figure2 Selective angiography of the celiac artery and its
branches: a hypervascularized mass in the second part of the duo-
denum is evident. The neoplasm contains micro-arterovenous fis-
tulae with stasis of the contrast medium.
undistinguishable from the more common adenocar-
cinoma. In our case, the previous surgery for pancre-
atic cyst may have been misleading in diagnostic
evaluation. Moreover, diagnostic imaging techniques
such as US,CT scan and endoscopy do not seem, in our
experience, to give specific, results.
A rise in circulating levels of somatostatin follo-
wing intravenous infusion of calcium and pentagastrin
has been described
9 as a diagnostic test in patients
affected by a "non functional" somatostatinoma, but
is should be considered that this technique has been
employed in already diagnosed cases, so its use as
a "true" diagnostic tool seems questionable if there
are not further elements suggestive of a somatos-
tatinoma. Possibly because of slow growth and non-
specific symptoms, the diagnosis is often late, and
metastases have been observed in 88% of cases of
somatosatinoma7. Tumor spread frequently affects
the liver (42%), as in our patient; other common
sites involved are regional lymphnodes (39%) and the
duodenum.
When technically feasible, surgical treatment seems
to be the only effective therapy for this type of neo-
plasms; the most suitable procedure is a duodenopan-
createctomy.
The role of adjuvant therapy is still debated, because
of the paucity of reported experiences. However,
a single more effective agent has not been defined to
date, chemotherapy seems to be- as in our case- an
useful tool for prolonged control of distant meta-
stases6, 7,1 o, 11.
Figure 3 Microphotography of the intraoperative biopsy of liver metastasis (immunohistochemistry with somatostatin antiserum).266 A.M.R. FERRANTE et al.
CONCLUSIONS
Somatostatinoma is seldom diagnosed preoperatively:
physical examination, clinical symptoms and imaging
techniques do not give specific results. Duodenal types
are generally asymptomatic from the hormonal aspect
and may not produce, as in the case we reported, high
levels of circulating somatostatin.
The prognosis of resectable somatostatinoma is
much better than that described in pancreatic and
biliary adenocarcinomas, so the main goal is to achieve,
mainly with immunohistochemistry, a correct diagnosis,
in order to plan effective surgery. Cytotoxic therapy may
be given in diffuse neoplasms with acceptable results.
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